AG Plus Diagnostics, the quantitative point-of-care diagnostic test company based at Colworth Park, has recently been awarded its first Innovate UK grant. This was awarded as part of Innovate UK’s Analysis for Innovators competition. AG Plus will use the funding to collaborate with the UK’s National Physical Laboratory (NPL) on a project to develop and refine the manufacture of ket AG Plus cartridge components.
‘AG Plus is delighted to receive this award and to partner again with NPL.’ said Christopher Getley, AG Plus’s Chairman, ‘it forms an important part of AG Plus’s current manufacturing scale-up plan in order to meet the 2018 launch of our first human clinical trial diagnostic test.’
The AG Plus clinical diagnostic test platform utilises electrochemical immunoassay technology in a patented microfluidic cartridge format. It is a truly point-of-care platform consisting of a handheld reader and single use cartridges. The unique electrochemical signalling and measurement system allows fully quantitative, extremely sensitive and accurate results to be obtained in under 10 minutes. AG Plus is a business-to-business company that has, over the last 12 months, built key relationships with both pharmaceutical and diagnostics companies.